Andere talen Celltrion, Inc.

Aandelen

A068270

KR7068270008

slotkoers Korea S.E. Andere beurzen 00:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
179.500 ^KRW	-0,11%		+4,97%	-10,92%

17/04	Celltrion, Inc. (KOSE:A068270) kondigt een aandeleninkoopprogramma aan voor 436.047 aandelen.	CI
17/04	Celltrion, Inc. autoriseert een terugkoopplan.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Market Share of Celltrion’s Remsima Rises to 74% in Europe	24/04
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	22/04
Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	17/04
Celltrion, Inc. authorizes a Buyback Plan.	17/04
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.	28/03
Updates On Aflibercept BPCIA Litigation	26/03
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.	26/03
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.	20/03
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US	18/03
Celltrion's Autoimmune Disease Treatment Hits US Markets	18/03
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed	06/03
Celltrion Announces 75 Billion Won Share Buyback Plan	06/03
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)	05/03
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.	05/03
Celltrion, Inc. authorizes a Buyback Plan.	05/03
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	29/02
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings	29/02
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25%	29/02
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Celltrion, Inc.

Aandelen

A068270

KR7068270008

Andere talen

Filters